| Name | Title | Contact Details |
|---|---|---|
Gurudutt Bansal |
Vice President of Engineering and Managing Director of Operations | Profile |
CTS is a designer and manufacturer of sensors, actuators and electronic components for original equipment manufacturers (OEMs) in the aerospace, communications, defense, industrial, information technology, medical and transportation markets. CTS aims to be a leading provider of sensing and motion devices as well as connectivity components, enabling an intelligent and seamless world. This is accomplished by maintaining a strategy of investing in innovative products that fulfil the CTS value proposition - sense, connect and move. CTS manufactures products in North America, Europe and Asia.
Redefined Ultra-Low-Power, Full System-on-Chip Solutions PsiKick develops next generation ultra-low-power wireless sensing systems with the lowest-power sensing devices in the world. Fully integrated and silicon-proven, the system-on-chip solutions operate at up to 1/1,000th the power of existing best-in-class "low power" solutions. Their extreme energy efficiency enables them to be powered without a battery from a variety of harvested energy modalities including vibration, thermal gradients, solar, RF, or piezo actuation.
Catalyst Semiconductor, Inc. is a Santa Clara, CA-based company in the Computers and Electronics sector.
Terradex Inc is a Palo Alto, CA-based company in the Computers and Electronics sector.
Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.